Trial Profile
A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2021
Price :
$35
*
At a glance
- Drugs GB 001 (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Biomarker
- Sponsors Pulmagen Therapeutics
- 17 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2012 Planned End Date changed from 1 Dec 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
- 19 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.